<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331913</url>
  </required_header>
  <id_info>
    <org_study_id>FAHZU-2017-025</org_study_id>
    <nct_id>NCT03331913</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin for Trigeminal Neuralgia</brief_title>
  <acronym>EASTERN</acronym>
  <official_title>The Efficacy and Safety of Botulinum Toxin for the Treatment of Trigeminal Neuralgia: Comparison of Two Different Treatment Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Zhengzhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trigeminal neuralgia (TN) is one of the most painful and common types of neuropathic pain&#xD;
      encountered by clinicians. It is typically treated pharmacologically with anticonvulsants,but&#xD;
      these can be ineffective, or can lose their effectiveness over time.Botulinum toxin type A&#xD;
      (BoNT-A) is an exotoxin released by the Gram-positive, anaerobic bacillus Clostridium&#xD;
      botulinum that causes flaccid paralysis by blocking neurotransmitter release by axonal&#xD;
      terminals. As a contaminant, it is the cause of potentially lethal botulism poisoning;&#xD;
      however, as a drug, it has been widely used in the treatment of dystonia, as well as for&#xD;
      non-surgical cosmetic treatment. More recently, studies investigating the ability of BoNT-A&#xD;
      to treat pain have been increasing. In 2012, the investigators reported the results of a&#xD;
      randomized, double-blind, and placebo-controlled trial in which subcutaneous injection of&#xD;
      BoNT-A at the site of pain provided long-term effective relief in TN. The investigators noted&#xD;
      that adverse effects were mild, as well. Other studies on TN have estimated the effectiveness&#xD;
      of BoNT-A treatment in TN to be 47-73%. However, BoNT-A treatment is still ineffective in&#xD;
      more than 30% of patients.In this study, the investigators investigate whether different&#xD;
      treatment methods have different efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pain relief was defined as â‰¥50% reduction in Visual Analogue Scale score which is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>1 week</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>2 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>3 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>5 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>6 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>7 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>9 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>10 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>11 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Visual Analogue Scale score is an 11 point scale from 0 - 10 with 0 being no headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall response to treatment on the Patient Global Impression of Change</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety which is assessed by adverse reactions</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse reactions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Trigeminal Neuralgia</condition>
  <arm_group>
    <arm_group_label>intradermal / submucosal injection group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intradermal / submucosal injection at pain area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-masseter injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra-masseter injection on the ipsilateral of pain involved</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin type A (intradermal / submucosal injection at pain area)</intervention_name>
    <description>Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia</description>
    <arm_group_label>intradermal / submucosal injection group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin type A (intra-masseter injection on the ipsilateral of pain involved)</intervention_name>
    <description>Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia</description>
    <arm_group_label>intra-masseter injection group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Clinical diagnosis of classical trigeminal neuralgia according to the ICHD III (beta)&#xD;
&#xD;
          -  The pain involved the gingiva&#xD;
&#xD;
          -  Signed informed consent prior to entering study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  comorbid diseases that may be exacerbated by botulinum toxin type A (e.g., myasthenia&#xD;
             gravis, motor neuron disease, or Lambert-Eaton syndrome).&#xD;
&#xD;
          -  receiving drugs with neuromuscular junction toxicity 1 week before botulinum toxin&#xD;
             type A treatment (e.g. quinine, aminoglycosides or penicillamine)&#xD;
&#xD;
          -  had an infection of the skin or mucosa at any of the injection sites.&#xD;
&#xD;
          -  psychiatric illness.&#xD;
&#xD;
          -  malignancy.&#xD;
&#xD;
          -  pregnancy or lactation.&#xD;
&#xD;
          -  currently participating or previously participated in any investigational drug or&#xD;
             device study within 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuanjie Wu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xuanwu Hospital Captial Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chuanjie Wu, MD</last_name>
    <phone>008615903676787</phone>
    <email>wuchuanjie8557@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yajun Lian, MD</last_name>
    <phone>008613838367143</phone>
    <email>lianyajun369@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuanwu Hospital Captial Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xunming Ji, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guizhou Provincial People's Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yajun Lian, MD</last_name>
      <phone>008613838367143</phone>
      <email>lianyajun369@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangtan Central Hospital</name>
      <address>
        <city>Xiangtan</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Liang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzhou People's Hospital</name>
      <address>
        <city>Luzhou</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhou, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 22, 2018</last_update_submitted>
  <last_update_submitted_qc>November 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Chuanjie Wu</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trigeminal Neuralgia</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

